Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009)
Not Applicable
Completed
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000006340
- Lead Sponsor
- orth-East Japan Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 345
Inclusion Criteria
Not provided
Exclusion Criteria
1. NSCLC harboring T790M mutation 2. With massive effusion that require drainage 3. With symptomatic brain metastasis 4. With severe co-morbidities 5. With ineligible conditions judged by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival, second PFS in gefitinib alone arm, and Overall survival
- Secondary Outcome Measures
Name Time Method